TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9314462
Drug: Monthly intramuscular
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly intramuscular injections of benzathine penicillin G
Study: 16281190
Drug: Single-session modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session modified behavioral treatment (SSBT)
Study: 12061670
Drug: Subcutaneous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous erythropoietin (600 U/kg per week) and oral iron (3 mg/kg per day)
Study: 9706280
Drug: Warfarin stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin stroke prophylaxis
Study: 339132
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg/day for 2 months
Study: 31078463
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg orally twice daily and pembrolizumab 200 mg intravenously for 30 min on day 8 and every 3 weeks for cycles of 6 weeks for up to 2 years, followed by escalating doses of axitinib (2-10 mg) plus flat dose pembrolizumab.
Study: 15763453
Drug: Terbutaline 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 6 mg
Study: 10102971
Drug: Asacol (mesalazine)
Normalized name: mesalamine Rectal Foam [Asacol]
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asacol (mesalazine) 1.2 g daily for 12 months in Group A (1-2 years remission)
Study: 10102971
Drug: Asacol (mesalazine)
Normalized name: mesalamine Rectal Foam [Asacol]
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asacol (mesalazine) 1.2 g daily for 12 months in Group B (over 2 years remission)
Study: 429787
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine containing the recombinant of A/Victoria/3/75 with A/PR/8/34 virus
Study: 30308538
Drug: Short (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short (24 hours) antibiotic administration
Study: 30308538
Drug: Extended (>24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended (>24 hours) antibiotic administration
Study: 23225308
Drug: Diclofenac suppository-nabumetone
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository-nabumetone combination therapy
Study: 23225308
Drug: Nabumetone administration
Normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabumetone administration
Study: 21647699
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration (5 l/min) during spontaneous breathing in diabetic participants
Study: 21647699
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration (5 l/min)
Study: 8538183
Drug: High-dose 13-cis-retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose 13-cis-retinoic acid (13cRA)
Study: 8538183
Drug: High-dose followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose followed by low-dose 13-cis-retinoic acid (13cRA)
Study: 8538183
Drug: Adjuvant high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant high-dose 13-cis-retinoic acid (13cRA)
Study: 2142026
Drug: CGS 16949A
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 16949A 0.3 mg twice daily
Study: 2142026
Drug: CGS 16949A
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 16949A 1.0 mg twice daily
Study: 2142026
Drug: CGS 16949A
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 16949A 2.0 mg twice daily
Study: 2142026
Drug: CGS 16949A
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 16949A 0.1 mg twice daily
Study: 2142026
Drug: CGS 16949A
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 16949A (all doses)
Study: 23558857
Drug: Attribution retraining
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attribution retraining group therapy (ARGT)
Study: 15389174
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy in addition to the stay-active concept
Study: 9553435
Drug: Extracorporeal ultraviolet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal ultraviolet blood irradiation (EUVBR) with antibiotic therapy
Study: 7851112
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with beta-carotene (30 mg daily)
Study: 26994091
Drug: Ritonavir-boosted lopinavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted lopinavir (400/100 mg) with tenofovir disoproxil/emtricitabine (245/200 mg) once daily
Study: 26994091
Drug: Maraviroc (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (300 mg) with tenofovir disoproxil/emtricitabine (245/200 mg) once daily
Study: 20388648
Drug: Randomized treatments
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatments with n-3 polyunsaturated fatty acid or rosuvastatin
Study: 15754239
Drug: Operative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative therapy (IVO)
Study: 15754239
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy followed by operative intervention
Study: 7772514
Drug: High-dose vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vincristine (4 mg/m2 over 4 d) combined with fractionated total body irradiation (F-TBI) (200 cGy x 2 over 3 d) and cyclophosphamide (60 mg/kg for 2 d) in AlloBMT
Study: 7772514
Drug: High-dose vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vincristine (4 mg/m2 over 4 d) combined with fractionated total body irradiation (F-TBI) (200 cGy x 2 over 3 d) and cyclophosphamide (60 mg/kg for 2 d) in ABMT
Study: 2189452
Drug: Saline 10
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 10 ml
Study: 457017
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Allopurinol
Study: 457017
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Benzbromarone
Study: 457017
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Allopurinol and Benzbromarone
Study: 26840133
Drug: Metformin (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (3.0 g per day)
Study: 24354519
Drug: Tissue kallikrein
Normalized name: Tissue kallikrein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue kallikrein treatment (intravenous infusion of tissue kallikrein 0.15 PNAU/d for 7 days, followed by oral pancreatic kallikrein enteric-coated tablet 240 U, 3 times a day)
Study: 24354519
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no tissue kallikrein treatment)
Study: 20980943
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg intravenous N-acetylcysteine (NAC)
Study: 16265685
Drug: Quinapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10 mg/day)
Study: 1619103
Drug: Low-dose cranial
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cranial radiation therapy
Study: 25029210
Drug: Fr +
Normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fr + G (13C‐labelled fructose, unlabeled glucose, lipids and protein)
Study: 25029210
Drug: Fr +
Normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fr + G
Study: 23157043
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dinoprostone vaginal insert single dose
Study: 20517830
Drug: Clomifene +
Normalized name: clomifene
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomifene + Metformin (Metformin 850 mg twice a day for 8 weeks, Clomifene 100 mg per day for 5 days)
Study: 20517830
Drug: Clomifene only
Normalized name: Clomifene only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomifene only (100 mg per day for 5 days)
Study: 12527974
Drug: 12% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% CHO solution
Study: 12527974
Drug: 0% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% CHO solution
Study: 1508061
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen (50 or 100 micrograms/24 h) combined with oral progestogen (5 mg medroxyprogesterone acetate for 14 days each cycle)
Study: 30768383
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment with continued CBT or pharmacotherapy with sertraline
Study: 31492103
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) infusion (20 IU insulin with 10 mEq KCL in 50 ml glucose 40%)
Study: 31492103
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) pretreatment after cardiopulmonary bypass
Study: 28196160
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + SMV (1.2 mg Simvastatin gel)
Study: 26270952
Drug: Normalisation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normalisation of SF by 3-weekly erythrocytapheresis
Study: 26270952
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment with 3-weekly plasmapheresis (no normalisation of SF)
Study: 23568224
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg for 4 days, coadministration with macitentan on day 5, continued for 19 additional days
Study: 23568224
Drug: Macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan 10 mg single oral dose
Study: 19583868
Drug: Restricted postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Restricted postoperative IV fluid regime (1.5 L/24 h)
Study: 19583868
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative IV fluid regime (2.5 L/24 h)
Study: 15218314
Drug: Adjuvant tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Adjuvant tegafur (TG) 500 mg/m²/day p.o. for 6 months plus four courses of mitomycin C (MMC) 10-20 mg/m² i.v. every 6 weeks
Study: 11674935
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic therapy (IVAT)
Study: 7846741
Drug: Famotidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (1 mg/kg/day) administered either intravenously or orally at a dose of 0.5 mg/kg twice a day (maximum: 40 mg/day)
Study: 7846741
Drug: Famotidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (1 mg/kg/day) administered either intravenously or orally
Study: 7846741
Drug: Famotidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (0.5 mg/kg twice a day for 8 weeks)
Study: 3072347
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg twice a day
Study: 3072347
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg twice a day
Study: 3072347
Drug: Ketanserin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (any dose) in white patients
Study: 3072347
Drug: Ketanserin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (any dose) in black patients
Study: 21266215
Drug: Ambulatory care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory care (outpatient treatment)
Study: 16715021
Drug: Manual lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual lymph drainage (ML)
Study: 3301001
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) nasal spray, 1.36 mg/attack
Study: 25600272
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (6% HP with and without n-HA)
Study: 23922054
Drug: Onartuzumab (IV)
Normalized name: Onartuzumab
DrugBank: Onartuzumab (DB11746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onartuzumab (IV) at doses between 4 and 30 mg/kg
Study: 23922054
Drug: Onartuzumab (IV)
Normalized name: Onartuzumab
DrugBank: Onartuzumab (DB11746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onartuzumab (IV) co-administered with oral erlotinib
Study: 19608210
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg GSE per day
Study: 19608210
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg GSE per day
Study: 18076799
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy using 5‐fluorouracil (5‐FU)
Study: 18076799
Drug: No perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative chemotherapy (Control)
Study: 12185407
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous citalopram
Study: 7697947
Drug: Single-dose zileuton
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose zileuton
Study: 7697947
Drug: Multiple-dose zileuton
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose zileuton
Study: 2094221
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg almitrine bismesylate (Vectarion)
Study: 2094221
Drug: Placebo-pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-pill
Study: 18042413
Drug: Millimetre wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Millimetre wave therapy (MWT)
Study: 12949688
Drug: Potentiated morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentiated morphine
Study: 9310224
Drug: 5‐FU/epi injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU/epi injectable gel (up to 2 cycles of ≤6 treatments)
Study: 9310224
Drug: 5‐FU/epi injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU/epi injectable gel (first cycle of treatment)
Study: 24555229
Drug: Emoxipin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emoxipin (150 mg daily)
Study: 24555229
Drug: Reamberin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin (400 ml daily)
Study: 24555229
Drug: Mexidol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (300 mg daily)
Study: 21953329
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg/h)
Study: 16567174
Drug: Betamethasone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (3 weekly doses starting at 34 weeks)
Study: 16567174
Drug: Prenatal steroids
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal steroids (in cohort study)
Study: 16567174
Drug: No prenatal
Normalized name: Vitafol-Nano Prenatal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prenatal steroids (in cohort study)
Study: 14653082
Drug: Losartan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (12 weeks treatment)
Study: 16967785
Drug: 100 mCi
Normalized name: FLUDEOXYGLUCOSE F 18 (10-100 MCI/ML) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mCi Iodine-131 (high dose)
Study: 16967785
Drug: 50 mCi
Normalized name: samarium Sm153 50 MCI/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mCi Iodine-131 (low dose)
Study: 14597947
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg 3 times per day)
Study: 10523009
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ACTH-(1-24) stimulation tests (0.1, 0.5, and 1.0 microg/1.73 m2)
Study: 10523009
Drug: Insulin hypoglycemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin hypoglycemia test (0.15 U/kg insulin)
Study: 10523009
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ACTH stimulation test (250-microg ACTH-(1-24))
Study: 10523009
Drug: 8-hour ACTH-(1-24)
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-hour ACTH-(1-24) infusion (250 microg at a constant rate over 8 h)
Study: 7552477
Drug: L-697,661 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-697,661 (50, 300, or 1,000 mg daily)
Study: 6108901
Drug: +cyanidanol-3 (Catechin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: +cyanidanol-3 (Catechin), 2 g/day
Study: 23416015
Drug: CysC ≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: CysC ≤ 95 mg/l and NT-proBNP ≤ 32 pg/ml
Study: 23525025
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg Alendronate weekly for eight weeks
Study: 23525025
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Alendronate daily for eight weeks
Study: 16893712
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg warfarin initiation nomogram
Study: 3318546
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg body wt.)
Study: 3318546
Drug: Methohexital (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (1 mg/kg)
Study: 24716641
Drug: Corticosteroids (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (mean daily dose)
Study: 20850833
Drug: Percutaneous tibial
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous tibial nerve stimulation (12 sessions, 30 minutes each, 3 times weekly)
Study: 18847313
Drug: Plerixafor (AMD3100)
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor (AMD3100) combined with G-CSF
Study: 12610195
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (300 mg/d) during cisplatin chemotherapy
Study: 12610195
Drug: Cisplatin chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin chemotherapy alone
Study: 28160272
Drug: Immediate initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate initiation of antiretroviral therapy
Study: 28160272
Drug: Deferred initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Deferred initiation of antiretroviral therapy
Study: 26331791
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg racemic venlafaxine (VLX)
Study: 9887236
Drug: IFN-alpha plus
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha plus ATRA (150 mg/m2/day orally in two divided doses)
Study: 9887236
Drug: IFN-alpha plus
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha plus 13cRA (1 mg/kg/day orally)
Study: 8005187
Drug: Pemirolast potassium
Normalized name: Pemirolast Potassium
DrugBank: Pemirolast (DB00885)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pemirolast potassium (TBX) 10 mg twice daily at 12 h intervals
Study: 8005187
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline formulation 100 mg twice daily at 12 h intervals
Study: 2689493
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination with polymyxin E, norfloxacin, amphotericin B and systemic antibiotic prophylaxis with trimethoprim
Study: 22403308
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg oral artesunate for three days followed by artemether-lumefantrine
Study: 22403308
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg oral artesunate for three days followed by artemether-lumefantrine
Study: 17554539
Drug: Maximum-tolerated doses
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum-tolerated doses (MTD) chemotherapy including 75 mg/m2 of cisplatin and 75 mg/m2 of docetaxel on day 1
Study: 17554539
Drug: Low-dose metronomic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metronomic (LDM) chemotherapy consisting of cisplatin 25 mg/m2 and docetaxel 25 mg/m2 given on weeks 1, 2, and 3
Study: 17056968
Drug: Pregabalin/Celecoxib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin/Celecoxib combination (400 mg/150 mg 1 h before and 200 mg/150 mg 12 h after surgery)
Study: 17056968
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg 1 h before and 200 mg 12 h after surgery)
Study: 17056968
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg 1 h before and 150 mg 12 h after surgery)
Study: 17056968
Drug: Pregabalin/Celecoxib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin/Celecoxib combination
Study: 2204472
Drug: ZnSO4 (660
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnSO4 (660 mg) per day
Study: 17276217
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with a fixed sling for 1 week followed by rehabilitation
Study: 15507072
Drug: Analgesic use
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic use (any)
Study: 15507072
Drug: Opioid analgesic
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesic use